YUMAB developed a novel pHLA display library that is used for the selection and screening of highly specific TCR-like antibodies from a proprietary human antibody library.
TCR-like antibodies are an emerging class of therapeutics as they allow the targeting of intracellular proteins which are displayed as peptides by MHC proteins on the cell surface. Thus, a novel epitope space of cancer targets can be addressed that had been undruggable with conventional antibodies so far. However, the potential risk for off-target binding of TCRs and TCR-like antibodies remains challenging and needs to be addressed.
Here, we present YUMAB's natural human pHLA display library and demonstrate how it can be used to select and screen for highly target specific antibodies using a library vs library approach. The resulting antibodies from this novel discovery platform are highly diverse and show superior binding characteristics as compared to reference antibodies. When tested in various T-cell engager formats, using YUMAB's proprietary CD3-specific VHH, the antibodies showed efficient and specific target cell killing.
Presenters
Philipp Kuhn
Dr. Philipp Kuhn is Vice President for Services & Operations at YUMAB, where he contributes to the development of innovative technologies and antibody products. Holding a PhD in Molecular Biotechnology and bringing around ten years of experience in antibody research, he possesses extensive expertise in antibody discovery and engineering, particularly using phage-display technology.
Sponsor
KACTUS
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
